Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...

Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...

Shuttle Pharmaceuticals SHPH stock declined by 25.6% to $0.32 during Friday's pre-market session. The company's market cap stands at $1.5 million. AirSculpt Technologies AIRS shares decreased by 16.33 ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...

Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...

Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target Light Up your Portfolio with Spark:Easily identify stocks' ...

EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 targetLight Up your Portfolio with Spark:Easily identify stocks' risks ...

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...

Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...

The headline numbers for Nektar (NKTR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Reports Q4 revenue $29.2M, consensus $36.66M. “The significant progress we made last year in advancing our immunology pipeline positions us for ...